Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced it will report first quarter 2021 financial results on Thursday, May 6, 2021 after the financial markets close, and host its annual shareholder meeting on May 19, 2021. Details for each is as follows:


GlobeNewswire Inc | Apr 29, 2021 09:00AM EDT

April 29, 2021

BOSTON, April 29, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced it will report first quarter 2021 financial results on Thursday, May 6, 2021 after the financial markets close, and host its annual shareholder meeting on May 19, 2021. Details for each is as follows:

Earnings Conference Call and Webcast Ziopharm will host a conference call and webcast for the investment community on May 6, 2021, at 4:30 p.m. EDT. The conference call can be accessed by dialing 855-327-6837 (U.S.andCanada) or 631-891-4304 (International). The passcode for the conference call is 10013973. A live webcast may be accessed using the link here, or by visiting the Investors section of the Ziopharm website at www.ziopharm.com. The call will be recorded and available for replay on the Companys website for approximately 90 days after the call.

Annual Meeting of StockholdersZiopharm will host its annual meeting virtually on May 19, 2021 at 9:00 am EDT. Shareholders and interested stakeholders may attend the meeting by visiting www.virtualshareholdermeeting.com/ZIOP2021. Shareholders can submit questions and vote their shares electronically during the meeting using the same link.

AboutZiopharm Oncology, Inc.Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the bodys immune system to treat the millions of people globally diagnosed with cancer each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology. Ziopharms pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viralSleeping Beautygene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufacturedSleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic collaborations with theNational Cancer Institute,The University of Texas MD Anderson Cancer Centerand Regeneron Pharmaceuticals. For more information, please visitwww.ziopharm.com.

Investor Relations Contact:Adam D. Levy, Ph.D., MBAEVP, Investor Relations and Corporate CommunicationsT: 508.552.9255E:alevy@ziopharm.com







Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC